Author

Lucas Roberto Rivabem Ferreira

Observed names: Ferreira, Lucas Roberto Rivabem, Lucas Roberto Rivabem Ferreira, Lucas Rivabem

Institutions: Hospital Universitario Virgen del Rocío, Hospital do Rocio

Observed institutions: Hospital Universitario Virgen del Rocío, Hospital do Rocio

ORCID: 0009-0004-6049-7503

Observed ORCID: 0009-0004-6049-7503

OpenAlex ID: A5027515712

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

2021 · Eduardo Ramacciotti, Leandro Barile Agati, et al. · The Lancet · 268

Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial

2023 · Huijie Bian, Liang Chen, et al. · Signal Transduction and Targeted Therapy · 19

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

2023 · Lívia Pimenta Bonifácio, Eduardo Ramacciotti, et al. · Revista da Sociedade Brasileira de Medicina Tropical · 10

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

2023 · Bonifácio, Lívia Pimenta, Ramacciotti, Eduardo, et al. · Figshare

Methylprednisolone Versus Dexamethasone in Patients with COVID-19 the MEDEX Clinical Trial

2023 · Rivabem Junior, Dalton Luiz, Dusilek, Cesar de Oliveira Lopes, et al. · Health Education and Public Health

Works count: 5

Citation count: 297

H-index: 3

I10-index: 3